Lumen Technologies Inc vs Tempus AI — how do they compare? Lumen Technologies Inc trades at $5.3 (market cap $5.73B), while Tempus AI trades at $70.95 (market cap $12.58B). The key difference: Tempus AI is far larger — about 2.2× Lumen Technologies Inc's market cap, and Tempus AI is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Tempus AI for 23 Days on average.
| LUMN | TEM | |
|---|---|---|
Market Cap | $5.73B | $12.58B |
Volume | 17,079,799 | 7,444,569 |
Sector | Media | Broad Market / Factor |
52-Week High | $11.83 | $99.28 |
52-Week Low | $5.53 | $41.55 |
Typical Hold Time | 40 Days | 23 Days |
Enterprise Value | $17.35B | $13.21B |
Signals from Pluang's Aura AI — not financial advice
Lumen Technologies (LUMN) trades at $5.28, down 10.66% in the last session, reflecting ongoing investor concerns. The stock shows bearish technical signals with mixed earnings performance - beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Despite revenue declining from $17.5B in 2022 to $12.4B in 2025, the company maintains strong operating cash flow of $4.7B and is strategically pivoting toward AI networking services.
LUMN presents a high-risk turnaround opportunity with significant debt burden ($17.5B long-term) and negative profitability metrics. The AI-focused strategy shows promise but faces execution risk against steep legacy revenue declines. Analyst consensus remains cautious with 61% hold ratings, suggesting investors await concrete evidence of sustainable growth before committing.
Tempus AI (TEM) trades at $71.46, up 1.66% with a bullish technical signal despite negative profitability metrics. The stock shows strong analyst support with 9 buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and 13 ESMO Congress presentations highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist at -$254M.
Outlook remains cautiously optimistic given strong institutional backing and AI healthcare growth potential, but profitability challenges and insider selling present near-term risks. The stock's valuation appears stretched with P/S of 8.61 and P/B of 28.27, requiring sustained revenue acceleration to justify current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →